Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans

Journal of Nuclear Medicine

Volumn 54, Issue 10, 2013, Pages 1760-1767

  Tavares, Adriana Alexandre S ^a   Batis, Jeffery C ^a,b   Papin, Caroline ^a,b   Jennings, Danna ^a,b   Alagille, David ^a,b   Russell, David S ^a,b   Vala, Christine ^a,b   Lee, Hsiaoju ^a,b   Baldwin, Ronald M ^a,b   Zubal, I George ^a,b   Marek, Kenneth L ^a,b   Seibyl, John P ^a,b   Barret, Olivier ^a,b   Tamagnan, Gilles D ^a,b  

^a Molecular NeuroImaging LLC   (United States)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

A2A receptors; Dosimetry; SPECT; Test retest

Indexed keywords

ADENOSINE A2A RECEPTOR; MNI 420 I 123; TRACER; UNCLASSIFIED DRUG; 7-(2-(4-(2-FLUORO-4-IODOPHENYL)PIPERAZIN-1-YL)ETHYL)-2-(FURAN-2-YL)-7H-PYRAZOLO(4,3-E)(1,2,4)TRIAZOLO(1,5-C)PYRIMIDIN-5-AMINE; FUSED HETEROCYCLIC RINGS; 7 (2 (4 (2 FLUORO 4 IODOPHENYL)PIPERAZIN 1 YL)ETHYL) 2 (FURAN 2 YL) 7H PYRAZOLO(4,3 E)(1,2,4)TRIAZOLO(1,5 C)PYRIMIDIN 5 AMINE; DIAGNOSTIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOSIMETRY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OCCIPITAL CORTEX; PARIETAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX; TEST RETEST RELIABILITY; WHOLE BODY IMAGING; BIOLOGICAL MODEL; BRAIN; CLINICAL TRIAL; DIAGNOSTIC USE; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; METABOLISM; MIDDLE AGED; RADIOMETRY; REPRODUCIBILITY; SCINTISCANNING; YOUNG ADULT; 123I-MNI-420; A2A RECEPTORS; TEST-RETEST;

ADULT; BRAIN; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INJECTIONS, INTRAVENOUS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RADIOMETRY; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

123I-MNI-420; A2A RECEPTORS; DOSIMETRY; SPECT; TEST-RETEST;

EID: 84891669667     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.119933     Document Type: Article

References (35)

1. 11C] SCH442416. Eur J Nucl Med Mol Imaging. 2005;32:405-413.
2. 11C]TMSX PET. Synapse. 2007;61:778-784.
3. 2A receptors in rats. Synapse. 2001;42:164-176.
4. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011;1808:1290-1308.
5. Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse. 1997;27:322-335.
6. 2A adenosine receptor antagonists for positron emission tomography (PET). Eur J Med Chem. 2006;41:7-15.
7. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem. 2002;80:262-270.
8. 2a receptor. Nature. 1997; 388:674-678.
9. 2A receptor knockout mice. Br J Pharmacol. 2001;134:68-77.
10. 2A receptors. Nucl Med Biol. 1997;24:187-191.
11. 2a receptor ligand. J Nucl Med. 1998;39: 498-503.
12. 123I]MNI-420: a novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nucl Med Biol. 2013;40:403-409.
13. Chang L-T. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;25:638-643.
14. 18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424-435.
15. Innis RB, Cunningham V, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27:1533-1539.
16. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661-670.
17. Logan J, Fowler JS, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
18. Stabin MG, Sparks R, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
19. International Commission on Radiological Protection (ICRP). Limits for intakes of radionuclides by workers. ICRP publication 30 (part 1). Ann ICRP. 1979;2(3-4).
20. 11C]TMSX PET in the striata of Parkinson's disease patients. PLoS ONE. 2011;6: e17338.
21. 11C]TMSX and positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:679-687.
22. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology. 2011;76:1811-1816.
23. 11C]WAY- 100635 binding parameters with reference tissue models: effect of violations of model assumptions. Nucl Med Biol. 2000;27:487-492.
24. 2A receptor ligands in rat, mouse and pig brain and first ex vivo results. Eur J Pharmacol. 2009;616:107-114.
25. Abi-Dargham A, Gandelman M, Zoghbi SS, et al. Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123- iomazenil. J Nucl Med. 1995;36:167-175.
26. 123I]epidepride SPECT in humans. J Nucl Med. 2000;41:1343-1351.
27. Booij J, Habraken JBA, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879-1884.
28. Seibyl JP, Laruelle M, Dyck CHv, et al. Reproducibility of iodine-123-FP-CIT SPECT brain measurement of dopamine transporters. J Nucl Med. 1996;37: 222-228.
29. 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med. 2005;46:1301-1309.
30. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283:2674-2679.
31. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol. 2001; 50:56-63.
32. 2A antagonists in PD. Neurology. 2002;58:1154-1160.
33. 123I]ADAM in healthy human subjects: preliminary results. Eur J Nucl Med Mol Imaging. 2003;30:132-136.
34. 123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med. 2004;18:337-344.
35. Dey HM, Seibyl JP, Stubbs JB, et al. Human biodistribution and dosimetry of the SPECT benzodiazepine receptor radioligand iodine-123-lomazenil. J Nucl Med. 1994;35:399-404.